ImmunoBrain Email Format
Biotechnology ResearchNew York, United States11-50 Employees
ImmunoBrain is a clinical-stage biotechnology company based in New York, focused on neurodegenerative diseases and aging by modulating the immune system. It aims to restore communication among brain immune cells and enhance the brain's natural repair processes, with its lead program centered on an antibody that targets the PD-1/PD-L1 immune checkpoint to address Alzheimer's disease. Its scientific approach draws on discoveries from Prof. Michal Schwartz's laboratory at the Weizmann Institute of Science. In March 2026, ImmunoBrain disclosed Phase 1b data for its IBC-Ab002 antibody and announced related presentations at the AD/PD conference in Copenhagen. These activities reflect ongoing clinical-stage development in neurodegeneration and immunotherapy.